The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
Open accessAbstract
Half of all human cancers lose p53 function by missense mutations, with an unknown fraction of these containing p53 in a self-aggregated amyloid-like state. Here we show that a cell-penetrating peptide, ReACp53, designed to inhibit p53 amyloid formation, rescues p53 function in cancer cell lines and in organoids derived from high-grade serous ovarian carcinomas (HGSOC), an aggressive cancer characterized by ubiquitous p53 mutations. Rescued p53 behaves similarly to its wild-type counterpart in regulating target genes, reducing cell proliferation and increasing cell death. Intraperitoneal administration decreases tumor proliferation and shrinks xenografts in vivo. Our data show the effectiveness of targeting a specific aggregation defect of p53 and its potential applicability to HGSOCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Peptide ReACp53 was described to prevent the amyloid-like aggregation of proteins with point mutations in p53-R248Q or p53-R175H.”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [134]
The cited source says what the claim attributes to it.
In the citing paper
“Treatment of ovarian cancer xenografts with ReACp53 resulted in decreased cell proliferation and tumor reduction [134].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Janzen, D. M., Tiourin, E., Salehi, J. A., Paik, D. Y., Lu, J. N., Pellegrini, M. A., & Memarzadeh, S. (2015) · Nature Communications · doi:10.1038/ncomms8956 · Cited by 69
Self-citationRetractedSiegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T. A., Chang, J. C. S., Markman, M. M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456
Atomic structures of amyloid cross-β spines reveal varied steric zippers
Sawaya, M. R., Sambashivan, S., Nelson, R. A., Ivanova, M. I., Sievers, S. A., Apostol, M. I., Thompson, M. J., Balbirnie, M., Wiltzius, J. J. W., McFarlane, H. T., et al. (2007) · Nature · doi:10.1038/nature05695 · Cited by 2,279
Self-citationThe first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Leaver-Fay (2011) · doi:10.1016/b978-0-12-381270-4.00019-6 · Cited by 1,904
Flagged first, then by citations
1 of the 61 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Protein Phase Separation: A New Phase in Cell Biology
Boeynaems, S., Alberti, S., Fawzi, N. L., Mittag, T., Polymenidou, M., Rousseau, F., Schymkowitz, J. W. H., Shorter, J., Wolozin, B. L., Bosch, L. V. D., et al. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.02.004 · Cited by 2,001
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889
Drugging p53 in cancer: one protein, many targets
Hassin, O., & Oren, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 771
The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches
Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 675
Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours
Yao, H., Lan, J., Li, C., Shi, H., Brosseau, J., Wang, H., Lu, H., Fang, C., Zhang, Y., Liang, L., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0375-6 · Cited by 581
Targeting mutant p53 for cancer therapy: direct and indirect strategies
Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., Shen, J., Cai, L., Cai, X., & Chen, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01169-0 · Cited by 576
Structural Studies of Amyloid Proteins at the Molecular Level
Eisenberg, D. S., & Sawaya, M. R. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045104 · Cited by 528
Self-citationTherapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
The activities of amyloids from a structural perspective
Riek, R., & Eisenberg, D. S. (2016) · Nature · doi:10.1038/nature20416 · Cited by 514
Self-citationUnderstanding the complexity of p53 in a new era of tumor suppression
Liu, Y., Su, Z., Tavana, O., & Gu, W. J. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 538
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246
Cooks, T., Pateras, I. S., Jenkins, L. M. M., Patel, K., Robles, A. I., Morris, J., Forshew, T., Appella, E., Gorgoulis, V. G., & Harris, C. C. (2018) · Nature Communications · doi:10.1038/s41467-018-03224-w · Cited by 497
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
Mutant p53 as a target for cancer treatment
Duffy, M. J., Synnott, N. C., & Crown, J. P. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.023 · Cited by 369
Zhou, G., Liu, Z., & Myers, J. N. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25592 · Cited by 355
Phase Separation: Linking Cellular Compartmentalization to Disease
Aguzzi, A., & Altmeyer, M. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.03.004 · Cited by 343
Gain-of-function mutant p53 in cancer progression and therapy
Zhang, C., Liu, J., Xu, D., Zhang, T., Hu, W., & Feng, Z. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa040 · Cited by 358
Prions, prionoids and protein misfolding disorders
Scheckel, C., & Aguzzi, A. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0011-4 · Cited by 311
Mechanisms and Functions of Spatial Protein Quality Control
Sontag, E. M., Samant, R. S., & Frydman, J. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014616 · Cited by 276
Phan, N., Hong, J. J., Tofig, B., Mapua, M., Elashoff, D., Moatamed, N. A., Huang, J., Memarzadeh, S., Damoiseaux, R., & Soragni, A. (2019) · Communications Biology · doi:10.1038/s42003-019-0305-x · Cited by 269
Self-citationAtomic structures of TDP-43 LCD segments and insights into reversible or pathogenic aggregation
Guenther, E. L., Cao, Q., Trinh, H., Lu, J., Sawaya, M. R., Cascio, D., Boyer, D. R., Rodríguez, J. A., Hughes, M. P., & Eisenberg, D. S. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0064-2 · Cited by 254
Self-citationMutant p53 in cancer therapy—the barrier or the path
Zhou, X. Y., Hao, Q., & Lu, H. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy072 · Cited by 249
Mutant p53 in Cancer Progression and Targeted Therapies
Zhu, G., Pan, C., Bei, J., Li, B., Chen, L., Xu, Y., & Fu, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.595187 · Cited by 230
TP53 gain-of-function mutation promotes inflammation in glioblastoma
Ham, S. W., Jeon, H.-Y., Jin, X., Kim, E.-J., Kim, J.-K., Shin, Y. J., Lee, Y., Kim, S. H., Lee, S. Y., Seo, S., et al. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0126-3 · Cited by 213
Treating p53 Mutant Aggregation-Associated Cancer
Kanapathipillai, M. (2018) · Cancers · doi:10.3390/cancers10060154 · Cited by 220
Balasubramanian, A., Hsu, A. Y.-H., Ghimire, L., Tahir, M., Devant, P., Fontana, P., Du, G., Liu, X., Dang, F., Kambara, H., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adn1452 · Cited by 240
Translating p53-based therapies for cancer into the clinic
Peuget, S., Zhou, X., & Selivanova, G. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-023-00658-3 · Cited by 208
Uversky, V. N. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111874 · Cited by 196
Han, Y., Kim, B., Cho, U., Park, I. S., Kim, S. I., Dhanasekaran, D. N., Tsang, B. K., & Song, Y. S. (2019) · Oncogene · doi:10.1038/s41388-019-0949-5 · Cited by 190
Amyloid assembly and disassembly
Chuang, E., Hori, A. M., Hesketh, C. D., & Shorter, J. (2018) · Journal of Cell Science · doi:10.1242/jcs.189928 · Cited by 188
Targeting the DNA Damage Response in OSCC with TP 53 Mutations
Lindemann, A., Takahashi, H., Patel, A. A., Osman, A. A., & Myers, J. N. (2018) · Journal of Dental Research · doi:10.1177/0022034518759068 · Cited by 167
Exploring the multiple roles of guardian of the genome: P53
Feroz, W., & Sheikh, A. M. A. (2020) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-020-00089-x · Cited by 172
TP53 mutations in epithelial ovarian cancer
Zhang, Y., Cao, L., Nguyen, D., & Lu, H. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.08.40 · Cited by 156
YY1 regulates cancer cell immune resistance by modulating PD-L1 expression
Hays, E., & Bonavida, B. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.04.001 · Cited by 145
How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance
Stiewe, T., & Haran, T. E. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.05.001 · Cited by 143
Fundamentals of cross-seeding of amyloid proteins: an introduction
Ren, B., Zhang, Y., Zhang, M., Liu, Y., Zhang, D., Gong, X., Feng, Z., Tang, J., Chang, Y., & Zheng, J. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01871a · Cited by 139
p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis
Ghosh, S., Salot, S., Sengupta, S., Navalkar, A., Ghosh, D., Jacob, R. S., Das, S., Kumar, R., Jha, N. N., Sahay, S., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.105 · Cited by 136
Phase-to-Phase With Nucleoli – Stress Responses, Protein Aggregation and Novel Roles of RNA
Latonen, L. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00151 · Cited by 134
O -GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation
Zhu, Q., Wang, H., Chai, S., Xu, L., Lin, B., Yi, W., & Wu, L. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2216796120 · Cited by 136
Palanikumar, L., Karpauskaite, L., Al‐Sayegh, M., Chehade, I., Alam, M., Hassan, S., Maity, D., Ali, L., Kalmouni, M., Hunashal, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23985-1 · Cited by 126
Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer
Silva, J. L., Cino, E. A., Soares, I. N., Ferreira, V. F., & de Oliveira, G. A. P. (2017) · Accounts of Chemical Research · doi:10.1021/acs.accounts.7b00473 · Cited by 121
Structure-based inhibitors of amyloid beta core suggest a common interface with tau
Griner, S. L., Seidler, P., Bowler, J., Murray, K. A., Yang, T. P., Sahay, S., Sawaya, M. R., Cascio, D., Rodriguez, J. A., Philipp, S., et al. (2019) · eLife · doi:10.7554/elife.46924 · Cited by 121
Self-citationYang, Z., Xu, H., & Zhao, X. (2020) · Advanced Science · doi:10.1002/advs.201903718 · Cited by 124
Atomic-level evidence for packing and positional amyloid polymorphism by segment from TDP-43 RRM2
Guenther, E. L., Ge, P., Trinh, H., Sawaya, M. R., Cascio, D., Boyer, D. R., Gonen, T., Zhou, Z. H., & Eisenberg, D. S. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0045-5 · Cited by 125
Self-citationThe Function of the Mutant p53-R175H in Cancer
Chiang, Y.-T., Chien, Y., Lin, Y., Wu, H.-H., Lee, D., & Yu, Y. (2021) · Cancers · doi:10.3390/cancers13164088 · Cited by 127
Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm
Tsafou, K., Tiwari, P. B., Forman-Kay, J. D., Metallo, S. J., & Toretsky, J. A. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.04.008 · Cited by 113
Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5
Vogiatzi, F., Brandt, D. T., Schneikert, J., Fuchs, J., Grikscheit, K., Wanzel, M., Pavlakis, E., Charles, J. P., Timofeev, O., Nist, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612711114 · Cited by 99
Ethical issues in human organoid and gastruloid research
Munsie, M., Hyun, I., & Sugarman, J. (2017) · Development · doi:10.1242/dev.140111 · Cited by 111
Rising horizon in circumventing multidrug resistance in chemotherapy with nanotechnology
Choudhury, H., Pandey, M., Yin, T. H., Kaur, T., Jia, G. W., Tan, S. Q. L., Weijie, H., Yang, E. K. S., Keat, C. G., Bhattamisra, S. K., et al. (2019) · Materials Science and Engineering C · doi:10.1016/j.msec.2019.04.005 · Cited by 108
Phase separation of p53 precedes aggregation and is affected by oncogenic mutations and ligands
Petronilho, E. C., Pedrote, M. M., Marques, M. A., Passos, Y. M., Mota, M. F., Jakobus, B., de Sousa, G. D. S., da Costa, F. P., Felix, A. L., Ferretti, G. D. S., et al. (2021) · Chemical Science · doi:10.1039/d1sc01739j · Cited by 107
Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target
Schulz‐Heddergott, R., & Moll, U. M. (2018) · Cancers · doi:10.3390/cancers10060188 · Cited by 108
Li, C., Wan, Y., Zhang, Y., Fu, L., Blum, N. T., Cui, R., Wu, B., Zheng, R., Lin, J., Li, Z., et al. (2021) · Advanced Materials · doi:10.1002/adma.202103980 · Cited by 105
Aberrant phase separation and cancer
Taniue, K., & Akimitsu, N. (2021) · FEBS Journal · doi:10.1111/febs.15765 · Cited by 101
Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition
Saelices, L., Chung, K., Lee, J. H., Cohn, W., Whitelegge, J. P., Benson, M. D., & Eisenberg, D. S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805131115 · Cited by 98
Self-citationPeptides/Proteins Encoded by Non-coding RNA: A Novel Resource Bank for Drug Targets and Biomarkers
Zhu, S., Wang, J., He, Y., Meng, N., & Yan, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01295 · Cited by 97
Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors
Li, H., Zhang, J., TONG, J. H. M., Chan, A. W. H., Yu, J. Q., Kang, W., & To, K. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235999 · Cited by 100
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Song, B., Yang, P., & Zhang, S. (2024) · 癌症：英文版 · doi:10.1002/cac2.12520 · Cited by 103
Sun, Y., & Chakrabartty, A. (2017) · Biochemistry · doi:10.1021/acs.biochem.6b01088 · Cited by 105
Biomolecular condensates: new opportunities for drug discovery and RNA therapeutics
Conti, B. A., & Oppikofer, M. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.07.001 · Cited by 90
Rangel, L. P., Ferretti, G. D. S., Costa, C. L., Andrade, S. M. M. V., Carvalho, R. S., da Costa, D. C. F., & Silva, J. L. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004671 · Cited by 91
Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?Preprint
da Costa, D. C. F., de Oliveira, G. A. P., Cino, E. A., Soares, I. N., Rangel, L. P., & Silva, J. L. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a023614 · Cited by 89
Resveratrol prevents p53 aggregation in vitro and in breast cancer cells
da Costa, D. C. F., Campos, N., Santos, R. A., Guedes-da-Silva, F. H., Martins-Dinis, M. M. D. C., Zanphorlin, L. M., Ramos, C. H. I., Rangel, L. P., & Silva, J. L. (2018) · Oncotarget · doi:10.18632/oncotarget.25631 · Cited by 87
Oncogenic Gain of Function in Glioblastoma Is Linked to Mutant p53 Amyloid Oligomers
Pedrote, M. M., Motta, M. F., Ferretti, G. D. S., Norberto, D. R., Spohr, T. C. L. S., Lima, F. R. S., Gratton, E., Silva, J. L., & de Oliveira, G. A. P. (2020) · iScience · doi:10.1016/j.isci.2020.100820 · Cited by 90
Targeting Biomolecular Condensation and Protein Aggregation against Cancer
Silva, J. L., Foguel, D., Ferreira, V. F., Vieira, T. C. R. G., Marques, M. A., Ferretti, G. D. S., Outeiro, T. F., Cordeiro, Y., & de Oliveira, G. A. P. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00131 · Cited by 86
Multisite aggregation of p53 and implications for drug rescue
Wang, G., & Fersht, A. R. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700308114 · Cited by 82
Analysis and Interpretation of the Impact of Missense Variants in Cancer
Petrosino, M., Novak, L., Pasquo, A., Chiaraluce, R., Turina, P., Capriotti, E., & Consalvi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115416 · Cited by 81
(2019) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2019.08.002 · Cited by 78
Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma
Flynt, E., Bisht, K. K., Sridharan, V., Ortiz, M., Towfic, F., & Thakurta, A. (2020) · Cells · doi:10.3390/cells9020287 · Cited by 79
Tumor suppressor p53: from engaging DNA to target gene regulation
Sammons, M. A., Nguyen, T., McDade, S. S., & Fischer, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa666 · Cited by 78
Personalized chordoma organoids for drug discovery studies
Al Shihabi, A., Davarifar, A., Nguyen, H. T. L., Tavanaie, N., Nelson, S. D., Yanagawa, J., Federman, N., Bernthal, N., Hornicek, F., & Soragni, A. (2022) · Science Advances · doi:10.1126/sciadv.abl3674 · Cited by 75
Self-citationDrug screening model meets cancer organoid technology
Liu, C., Qin, T., Huang, Y., Li, Y., Chen, G., & Sun, C. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100840 · Cited by 75
Exploring the relationships between protein sequence, structure and solubility
Trainor, K., Broom, A., & Meiering, E. M. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2017.01.004 · Cited by 76
Frederick, K. K., Michaelis, V. K., Caporini, M. A., Andreas, L. B., Debelouchina, G. T., Griffin, R. G., & Lindquist, S. L. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619051114 · Cited by 70
Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
Zhang, S., Carlsen, L., Borrero, L. J. H., Seyhan, A. A., Tian, X., & El‐Deiry, W. S. (2022) · Biomolecules · doi:10.3390/biom12040548 · Cited by 75
Smet, F. D., Rubio, M. S., Hompes, D., Naus, E., Baets, G. D., Langenberg, T., Hipp, M. S., Houben, B., Claes, F., Charbonneau, S. K., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4872 · Cited by 75
Anomalous Dense Liquid Condensates Host the Nucleation of Tumor Suppressor p53 Fibrils
Safari, M. S., Wang, Z., Tailor, K., Kolomeisky, A. B., Conrad, J. C., & Vekilov, P. G. (2019) · iScience · doi:10.1016/j.isci.2019.01.027 · Cited by 70
The “Jekyll and Hyde” Actions of Nucleic Acids on the Prion-like Aggregation of Proteins
Silva, J. L., & Cordeiro, Y. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.733428 · Cited by 67
Patient-Derived Organoids as a Model for Cancer Drug Discovery
Rae, C. J., Amato, F., & Braconi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073483 · Cited by 74
da Costa, D. C. F., Fialho, E., & Silva, J. L. (2017) · Molecules · doi:10.3390/molecules22061014 · Cited by 68
It’s Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy
Kung, C.-P., & Weber, J. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818744 · Cited by 71
Wawrzynów, B., Żylicz, M., & Żylicz, M. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.12.004 · Cited by 65
Mesoscopic protein-rich clusters host the nucleation of mutant p53 amyloid fibrils
Yang, D. S., Saeedi, A., Davtyan, A., Fathi, M., Sherman, M. B., Safari, M. S., Klindziuk, A., Barton, M. C., Varadarajan, N., Kolomeisky, A. B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2015618118 · Cited by 64
Structural and Drug Targeting Insights on Mutant p53
Gomes, A. S., Ramos, H., Inga, A., Sousa, E., & Saraiva, L. (2021) · Cancers · doi:10.3390/cancers13133344 · Cited by 63
The algal polysaccharide ulvan suppresses growth of hepatoma cells
Zhao, C., Lin, G., Wu, D., Liu, D., You, L., Högger, P., Simal‐Gándara, J., Wang, M., da Costa, J. G. M., Marunaka, Y., et al. (2020) · Food Frontiers · doi:10.1002/fft2.13 · Cited by 63
Aggregation tendencies in the p53 family are modulated by backbone hydrogen bonds
Cino, E. A., Soares, I. N., Pedrote, M. M., de Oliveira, G. A. P., & Silva, J. L. (2016) · Scientific Reports · doi:10.1038/srep32535 · Cited by 65
Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket
Pradhan, M. R., Siau, J. W., Kannan, S., Nguyen, M. N., Ouaray, Z., Kwoh, C. K., Lane, D. P., Ghadessy, F. J., & Verma, C. S. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1314 · Cited by 63
Functional Mammalian Amyloids and Amyloid-Like Proteins
Rubel, M. S., Fedotov, S. A., Grizel, A. V., Sopova, J. V., Malikova, O. A., Chernoff, Y. O., & Rubel, A. A. (2020) · Life · doi:10.3390/life10090156 · Cited by 61
Krotee, P., Griner, S. L., Sawaya, M. R., Cascio, D., Rodríguez, J. A., Shi, D., Philipp, S., Murray, K. A., Saelices, L., Lee, J. H., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.806109 · Cited by 62
Self-citationAutophagy as an emerging therapy target for ovarian carcinoma
Zhan, L., Zhang, Y., Wang, W., Song, E., Fan, Y., Li, J., & Wei, B. (2016) · Oncotarget · doi:10.18632/oncotarget.13080 · Cited by 60
Exploring Dysregulated Signaling Pathways in Cancer
Nisar, S., Hashem, S., Macha, M. A., Yadav, S. K., Muralitharan, S., Therachiyil, L., Sageena, G., Al‐Naemi, H. A., Haris, M., & Bhat, A. A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200115095937 · Cited by 60
Prion-like p53 Amyloids in Cancer
Navalkar, A., Ghosh, S., Pandey, S., Paul, A., Datta, D., & Maji, S. K. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00796 · Cited by 56
The Status of p53 Oligomeric and Aggregation States in Cancer
de Oliveira, G. A. P., Petronilho, E. C., Pedrote, M. M., Marques, M. A., Vieira, T. C. R. G., Cino, E. A., & Silva, J. L. (2020) · Biomolecules · doi:10.3390/biom10040548 · Cited by 58
Identification of Small Molecules that Modulate Mutant p53 Condensation
Lemos, C., Schulze, L., Weiske, J., Meyer, H., Braeuer, N., Barak, N. N., Eberspächer, U., Werbeck, N. D., Stresemann, C., Lange, M., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101517 · Cited by 56
Kehrloesser, S., Osterburg, C., Tuppi, M., Schäfer, B., Vousden, K. H., & Dötsch, V. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.75 · Cited by 56
Intracellularly Swollen Polypeptide Nanogel Assists Hepatoma Chemotherapy
Shi, B., Huang, K., Ding, J., Xu, W., Yu, Y., Liu, H., Yan, L., & Chen, X. (2017) · Theranostics · doi:10.7150/thno.16794 · Cited by 55
Organoid of ovarian cancer: genomic analysis and drug screening
Liu, H., Xia, B., Jin, M., & Lou, G. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02276-8 · Cited by 61
A NO/ROS/RNS cascaded-releasing nano-platform for gas/PDT/PTT/immunotherapy of tumors
Ding, M., Shao, K., Wu, L., Jiang, Y., Cheng, B., Wang, L., Shi, J., & Kong, X. (2021) · Biomaterials Science · doi:10.1039/d1bm00726b · Cited by 54
Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition
Iwanicki, M., Chen, H., Iavarone, C., Zervantonakis, I. K., Muranen, T. E., Novak, M., Ince, T. A., Drapkin, R., & Brugge, J. S. (2016) · JCI Insight · doi:10.1172/jci.insight.86829 · Cited by 54
Metadata
- Authors
- Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., Pellegrini, M., Memarzadeh, S., & Eisenberg, D. S.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of California, Los Angeles (US)
- Corresponding author
- Memarzadeh, Sanaz
- Eisenberg, David S.
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 29
- Issue
- 1
- Pages
- 90-103
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC4733364
- OpenAlex
- W2207474307
- Cited by
- 341
- References
- 61
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 29 · 2023: 31 · 2022: 42 · 2021: 29 · 2020: 32 · 2019: 35 · 2018: 39 · 2017: 33 · 2016: 28
- FWCI
- 13.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- NIH (1S10RR023718-01A2, AG-029430, R01CA183877)
- Pardee Foundation
- National Center for Advancing Translational Science (UL1TR000124)
- American Cancer Society (RSG-14-217-01-TBG)
- National Science Foundation (MCB 0958111)
- Jonsson Cancer Center Foundation
- Lynne Cohen Foundation
- Phase One Foundation
- Ovarian Cancer Circle Inspired by Robin Babbini
- Leath L. and Marcia L. Millen Family Fund
- G.O. Discovery Lab Foundation
- HHMI
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- p53, amyloid-like aggregation, p53 missense mutations, cell-penetrating peptides, high-grade serous ovarian cancer, organoids, xenografts, cell proliferation, apoptosis
- MeSH terms
- Animals, Cell Line, Cells, Cultured, Disease Models, Animal, Female, Humans, Mice, Transgenic, Ovarian Neoplasms, Tumor Suppressor Protein p53, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
